A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
The objective of this trial is to assess anti-tumour activity of BI 754091 as monotherapy and of BI 754091 in combination with BI 836880 in patients with unresectable or metastatic squamous cell carcinoma of the anal canal who progressed on or after chemotherapy.
Anal Canal Squamous Cell Carcinoma
DRUG: BI 754091|DRUG: BI 836880
Objective response (OR), up to 3 years
Duration of objective response (DoR), up to 3 years|Progression-free survival (PFS), up to 3 years|Overall survival (OS), up to 3 years|Disease control (DC), up to 3 years|Adverse events (AEs), up to 3 years|Drug related AEs from the time of treatment initiation until the end of the Residual Effect Period (REP), up to 3 years|Drug related AEs leading to dose reduction of BI 836880 and/or discontinuation of study treatment (i.e. both trial drugs), up to 3 years
The objective of this trial is to assess anti-tumour activity of BI 754091 as monotherapy and of BI 754091 in combination with BI 836880 in patients with unresectable or metastatic squamous cell carcinoma of the anal canal who progressed on or after chemotherapy.